In a small clinical trial, customized mRNA vaccines against high-risk skin cancers appeared to reduce the risk of cancer recurrence and death by nearly 50 percent over five years when compared with ...

KOAT health expert Dr. Barry Ramo says the vaccine has the potential to eliminate the disease.

By Kamal Choudhury and Mariam Sunny Jan 20 (Reuters) - Moderna and Merck said on Tuesday their experimental personalized ...

Five years ago, a group of high-risk skin cancer patients received a bespoke vaccine. The data is finally in, and the results ...

Long-term follow-up data from a phase 2b trial of Moderna and MSD's mRNA-based vaccine against melanoma, intismeran autogene (mRNA-4157), show an impressive 49% reduction in the risk of disease ...

A new comprehensive review from researchers at the Icahn School of Medicine at Mount Sinai details how decades of cancer vaccine research are converging into a new era of more precise, personalized, ...

He's lost his father, a brother, aunts, uncles and extended family members to cancer — many of them in their 30s and 40s.

In patients with high-risk melanoma, the personalized cancer vaccine intismeran autogene and Keytruda reduced the risk of ...

Early research suggests the immune system may one day be trained to prevent cancer in people with inherited risk.

A new experimental vaccine could slow down triple negative breast cancer and reduce its recurrence after treatment.

New research suggests that a breast cancer vaccine developed decades ago may have triggered a lasting immune memory response that can now be significantly boosted by a newly developed antibody.

NORTON, Zimbabwe (AP) — Lesotho’s Lishoeshoe soccer club was losing by four goals at halftime against South Africa’s Mamelodi ...